Collectively, these data demonstrate that GLP-1–MK-801 corrects hypertriglyceridaemia and hyperglycaemia with improved or similar efficacy to semaglutide in animal models of obesity and type 2 diabetes. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.